...that paragraph to me is more about the beneficial effect + outcome in early MPC treatment on limiting deleterious scar tissue replacement and subsequent reduction in LVEF rather than a description of specific MOA. I am intrigued by his reference to endothelium controlled signal pathways, disruption of which between endothelium and cardiocytes "has been implicated" in cardiac structural/functionsl abnormalities.
I guess I'm curious about MPC cardiac regenerative effects as well as immunomodulatory inflammatory effects that impede scar tissue + general degradation in myocardial function, control of which by itself may explain the beneficial results observed.
Nice. Thanks. More reading to do.
MSB's year is upon us. Strap in.
Ann: Half Year Financial Results Presentation, page-75
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |